Current chemical-fuel-driven nanomotors are driven by gas (e.g. H2, O2, NH3) which only provides motion ability, and can produce waste (e.g. Mg(OH)2, Pt). Here, inspired by endogenous biochemical reactions in the human body involving conversion of amino acid L-arginine to nitric oxide (NO) by NO synthase (NOS) or reactive oxygen species (ROS), we report on a nanomotor made of hyperbranched polyamide/L-arginine (HLA). The nanomotor utilizes L-arginine as fuel for the production of NO both as driving force and to provide beneficial effects, including promoting endothelialisation and anticancer effects, along with other beneficial by-products. In addition, the HLA nanomotors are fluorescent and can be used to monitor the movement of nanomotors in vivo in the future. This work presents a zero-waste, self-destroyed and self-imaging nanomotor with potential biological application for the treatment of various diseases in different tissues including blood vessels and tumours.
The treatment difficulties of venous thrombosis include short half-life, low utilization, and poor penetration of drugs at thrombus site. Here, we develop one kind of mesoporous/macroporous silica/platinum nanomotors with platelet membrane (PM) modification (MMNM/PM) for sequentially targeting delivery of thrombolytic and anticoagulant drugs for thrombus treatment. Regulated by the special proteins on PM, the nanomotors target the thrombus site and then PM can be ruptured under near-infrared (NIR) irradiation to achieve desirable sequential drug release, including rapid release of thrombolytic urokinase (3 hours) and slow release of anticoagulant heparin (>20 days). Meantime, the motion ability of nanomotors under NIR irradiation can effectively promote them to penetrate deeply in thrombus site to enhance retention ratio. The in vitro and in vivo evaluation results confirm that the synergistic effect of targeting ability from PM and motion ability from nanomotors can notably enhance the thrombolysis effect in both static/dynamic thrombus and rat model.
The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor sites accurately and properly activate complex immune responses. Herein, we design and prepare a kind of chemotactic nanomotor loaded with brain endothelial cell targeting agent angiopep-2 and anti-tumor drug (Lonidamine modified with mitochondrial targeting agent triphenylphosphine, TLND). Reactive oxygen species and inducible nitric oxide synthase (ROS/iNOS), which are specifically highly expressed in glioblastoma microenvironment, are used as chemoattractants to induce the chemotactic behavior of the nanomotors. We propose a precise targeting strategy of brain endothelial cells-tumor cells-mitochondria. Results verified that the released NO and TLND can regulate the immune circulation through multiple steps to enhance the effect of immunotherapy, including triggering the immunogenic cell death of tumor, inducing dendritic cells to mature, promoting cytotoxic T cells infiltration, and regulating tumor microenvironment. Moreover, this treatment strategy can form an effective immune memory effect to prevent tumor metastasis and recurrence.